SUBSCRIBE
SUBSCRIBE
News   Policy

UK’s NICE Turns Down GlaxoSmithKline’s Tyverb Offer

October 14, 2008 | 
1 min read
LONDON, Oct 14 (Reuters) - Britain's healthcare cost effectiveness watchdog NICE has rebuffed GlaxoSmithKline's latest bid to get its drug Tyverb - for women with advanced breast cancer - into the state health system, the company said on Tuesday.
Regulatory Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Government
HHS Will No Longer Recognize Employee Unions
August 25, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative collage human 3d hands body fragments needle injection gloves medical healthcare hospital virus prevention drawing background.
Vaccines
FDA Pulls Valneva’s Chikungunya Shot From Market Citing ‘Serious Safety Concerns’
August 25, 2025
 · 
2 min read
 · 
Tristan Manalac
Magnifying glass and various business graphs on light blue background
Regulatory
FDA To Publish Drug-Related Adverse Event Reports Daily
August 25, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: White House/
Tariffs
Trump Administration Settles on 15% Generic Drug Tariff Rate for EU
August 22, 2025
 · 
1 min read
 · 
Annalee Armstrong